Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
CARMIEL, Israel, Feb. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development production and commercialization of recombinant therapeutic... Biopharmaceuticals, Drug Delivery, Licensing Protalix BioTherapeutics, SarcoMed USA, alidornase alfa, sarcoidosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Israel Health | Marketing | Middle East Health | Partnerships | Pharmaceuticals | Respiratory Medicine | Sarcoidosis